GAIASO Theranostics exists to change outcomes in women’s cancers by developing more effective therapies, ultimately delivering longer, healthier and more dignified lives. 

We’re closing the gender gap in oncology by advancing a new generation of radiotheranostics. Built on the Affilin® protein-engineering platform and developed with our partners at PreMIT Pty Ltd, our programs combine precise tumour targeting, optimised biodistribution, and rational combinations to enhance efficacy.

Our urgent mission is to accelerate life-saving options for more women, worldwide.

GAIASO Theranostics

Org chart

Teams

Offices